Logo image of JAZZ

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

NASDAQ:JAZZ - Nasdaq - IE00B4Q5ZN47 - Common Stock - Currency: USD

100.34  -2.44 (-2.37%)

After market: 100.34 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to JAZZ. JAZZ was compared to 198 industry peers in the Pharmaceuticals industry. While JAZZ belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. JAZZ may be a bit undervalued, certainly considering the very reasonable score on growth This makes JAZZ very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year JAZZ was profitable.
JAZZ had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
JAZZ had a positive operating cash flow in each of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

JAZZ's Return On Assets of 4.66% is amongst the best of the industry. JAZZ outperforms 89.39% of its industry peers.
JAZZ has a Return On Equity of 13.68%. This is amongst the best in the industry. JAZZ outperforms 89.90% of its industry peers.
JAZZ's Return On Invested Capital of 5.29% is amongst the best of the industry. JAZZ outperforms 82.83% of its industry peers.
The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 41.77%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(5.29%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.66%
ROE 13.68%
ROIC 5.29%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

Looking at the Profit Margin, with a value of 13.77%, JAZZ belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
JAZZ's Profit Margin has declined in the last couple of years.
The Operating Margin of JAZZ (18.06%) is better than 85.35% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 89.05%, JAZZ belongs to the best of the industry, outperforming 89.90% of the companies in the same industry.
JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.06%
PM (TTM) 13.77%
GM 89.05%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
The number of shares outstanding for JAZZ has been reduced compared to 1 year ago.
Compared to 5 years ago, JAZZ has more shares outstanding
JAZZ has a worse debt/assets ratio than last year.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

JAZZ has an Altman-Z score of 1.50. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
JAZZ's Altman-Z score of 1.50 is fine compared to the rest of the industry. JAZZ outperforms 65.66% of its industry peers.
The Debt to FCF ratio of JAZZ is 4.54, which is a neutral value as it means it would take JAZZ, 4.54 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of JAZZ (4.54) is better than 86.36% of its industry peers.
A Debt/Equity ratio of 1.49 is on the high side and indicates that JAZZ has dependencies on debt financing.
JAZZ has a Debt to Equity ratio of 1.49. This is in the lower half of the industry: JAZZ underperforms 73.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF 4.54
Altman-Z 1.5
ROIC/WACC0.79
WACC6.71%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

A Current Ratio of 4.46 indicates that JAZZ has no problem at all paying its short term obligations.
JAZZ has a better Current ratio (4.46) than 68.69% of its industry peers.
JAZZ has a Quick Ratio of 3.99. This indicates that JAZZ is financially healthy and has no problem in meeting its short term obligations.
JAZZ has a better Quick ratio (3.99) than 65.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.46
Quick Ratio 3.99
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.67% over the past year.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 6.12% in the last year.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)15.67%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%31.47%
Revenue 1Y (TTM)6.12%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%7.53%

3.2 Future

The Earnings Per Share is expected to grow by 5.83% on average over the next years.
Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 5.31% on average per year.
EPS Next Y12.18%
EPS Next 2Y4.65%
EPS Next 3Y5.12%
EPS Next 5Y5.83%
Revenue Next Year6.18%
Revenue Next 2Y4.8%
Revenue Next 3Y5.34%
Revenue Next 5Y5.31%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 4.74 indicates a rather cheap valuation of JAZZ.
Based on the Price/Earnings ratio, JAZZ is valued cheaper than 95.96% of the companies in the same industry.
JAZZ is valuated cheaply when we compare the Price/Earnings ratio to 27.63, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 4.22 indicates a rather cheap valuation of JAZZ.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 96.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.85. JAZZ is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 4.74
Fwd PE 4.22
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaper than 91.92% of the companies in the same industry.
97.47% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 4.52
EV/EBITDA 6.3
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

JAZZ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)0.39
PEG (5Y)0.87
EPS Next 2Y4.65%
EPS Next 3Y5.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JAZZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (4/21/2025, 8:23:43 PM)

After market: 100.34 0 (0%)

100.34

-2.44 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners100.43%
Inst Owner Change0.34%
Ins Owners2.39%
Ins Owner Change4.37%
Market Cap6.09B
Analysts83.33
Price Target193.94 (93.28%)
Short Float %7.44%
Short Ratio5.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.58%
Min EPS beat(2)11.32%
Max EPS beat(2)17.85%
EPS beat(4)3
Avg EPS beat(4)0.23%
Min EPS beat(4)-37.13%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-2.11%
EPS beat(12)5
Avg EPS beat(12)-11.14%
EPS beat(16)9
Avg EPS beat(16)-5.08%
Revenue beat(2)1
Avg Revenue beat(2)0.24%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.71%
Min Revenue beat(4)-7.3%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-1.47%
Revenue beat(12)2
Avg Revenue beat(12)-1.76%
Revenue beat(16)3
Avg Revenue beat(16)-1.45%
PT rev (1m)2%
PT rev (3m)5.21%
EPS NQ rev (1m)-1.36%
EPS NQ rev (3m)6.9%
EPS NY rev (1m)6.23%
EPS NY rev (3m)6.88%
Revenue NQ rev (1m)0.3%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE 4.74
Fwd PE 4.22
P/S 1.5
P/FCF 4.52
P/OCF 4.37
P/B 1.49
P/tB N/A
EV/EBITDA 6.3
EPS(TTM)21.19
EY21.12%
EPS(NY)23.77
Fwd EY23.69%
FCF(TTM)22.19
FCFY22.12%
OCF(TTM)22.99
OCFY22.91%
SpS67
BVpS67.41
TBVpS-39.16
PEG (NY)0.39
PEG (5Y)0.87
Profitability
Industry RankSector Rank
ROA 4.66%
ROE 13.68%
ROCE 6.7%
ROIC 5.29%
ROICexc 7.27%
ROICexgc 38.48%
OM 18.06%
PM (TTM) 13.77%
GM 89.05%
FCFM 33.13%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexcg growth 3Y32.25%
ROICexcg growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score8
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 1.49
Debt/FCF 4.54
Debt/EBITDA 4.36
Cap/Depr 7.28%
Cap/Sales 1.18%
Interest Coverage 2.33
Cash Conversion 100.07%
Profit Quality 240.63%
Current Ratio 4.46
Quick Ratio 3.99
Altman-Z 1.5
F-Score8
WACC6.71%
ROIC/WACC0.79
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.67%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%31.47%
EPS Next Y12.18%
EPS Next 2Y4.65%
EPS Next 3Y5.12%
EPS Next 5Y5.83%
Revenue 1Y (TTM)6.12%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%7.53%
Revenue Next Year6.18%
Revenue Next 2Y4.8%
Revenue Next 3Y5.34%
Revenue Next 5Y5.31%
EBIT growth 1Y19.35%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year13.71%
EBIT Next 3Y6.85%
EBIT Next 5Y9.04%
FCF growth 1Y28.48%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y27.83%
OCF growth 3Y21.49%
OCF growth 5Y12.45%